NCT02866734

Diabetic Retinopathy Screening in Private Practice

Completed NA Last updated 11 October 2018

What this trial tests

NA trial testing Free screening group in Diabetic Retinopathy in 238 participants. Completed in 1 June 2018.

Timeline

1 September 2016

Primary endpoint
13 December 2017

1 June 2018

Quick facts

Lead sponsor	The University of Hong Kong
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	238
Start date	1 September 2016
Primary completion	13 December 2017
Estimated completion	1 June 2018
Sites	1 location across Hong Kong

Drugs / interventions tested

• Free screening group
• Pay screening group ($150)
• Pay screening group ($300)

Conditions studied

• Diabetic Retinopathy — all drugs for Diabetic Retinopathy →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Diabetic mellitus (DM) is a prevalent disease in Hong Kong (HK) and diabetic retinopathy (DR) is one of the most common complications of DM. Screening for DR is a cost-effective method to identify patients who are at risk of vision loss so that timely treatment can be provided to patients. In Hong Kong, the Hospital Authority has recently set up screening services (RAMP) in the government outpatient clinics and all DM patients attending these clinics will be screened at least once every two years and some every six months, according to their individual risks. However, those diabetic patients who attend the private sector for their primary care may not have access to this service.

Aim: This study from the University of Hong Kong aims to determine the characteristics of a sustainable approach to setting up an effective and quality-controlled screening service for DR in the private primary care sector of Hong Kong and to estimate the potential benefit to be gained in terms of impact on avoidable vision loss, costs of care and potential for further development of this model in chronic disease care.

Methods:A screening centre is being set up and a randomised study carried out in which screening will be offered at three different fee levels to subjects recruited by their general practitioner (GP). The following data will be collected (a) willingness to attend screening at the different fee levels (b) screening findings in terms of DR and other eye diseases (c) risk factors and other characteristics of those screened and unscreened. The information will allow us to estimate the level of fee which best combines effectiveness with sustainability in the longer term.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Screening for diabetic retinopathy with different levels of financial incentive in a randomized controlled trial.
   Lian JX, McGhee SM, So C, Kwong ASK, et al · · 2021 · cited 3× · PMID 33484625 · DOI 10.1111/jdi.13512